A meta-analysis of adjuvant randomized trials comparing anthracycline-based treatment with CMF suggested that TOP2A amplified predicted responsiveness to anthracycline-based chemotherapy in patients with early breast cancer. The gene discussed is TOP2A; the disease is breast carcinoma.